TB Research

Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis

Camus Nimmo, James Millard, Lucy van Dorp, Kayleen Brien, Sashen Moodley, Allison Wolf, Alison D. Grant, Nesri Padayatchi, et al. (11 authors)

The Lancet Microbe · 2020-08

Abstract

BACKGROUND: isolates from cohort studies in hospitals in KwaZulu-Natal, South Africa, to identify resistance-associated variants (RAVs) and assess the extent of clofazimine and bedaquiline cross-resistance. We also used a comprehensive dataset of whole-genome sequences to investigate the phylogenetic and geographical distribution of bedaquiline and clofazimine RAVs in southern Africa. METHODS: isolates. FINDINGS: frameshift mutations that may confer resistance. INTERPRETATION: . Roll-out of bedaquiline and clofazimine treatment in the setting of limited drug susceptibility testing could allow further spread of resistance. Designing strong regimens would help reduce the emergence of resistance. Drug susceptibility testing is required to identify where resistance does emerge. FUNDING: Wellcome Trust, National Institute of Allergy and Infectious Diseases and National Center for Advancing Translational Sciences of the National Institutes of Health.

MeSH terms

  • Bedaquiline
  • Clofazimine
  • Tuberculosis
  • Mycobacterium tuberculosis
  • Drug resistance
  • Biology
  • Population
  • Medicine